AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 33.8 |
Market Cap | 3.78B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.94 |
PE Ratio (ttm) | -36.13 |
Forward PE | n/a |
Analyst | Buy |
Ask | 34.09 |
Volume | 7,062,316 |
Avg. Volume (20D) | 4,385,203 |
Open | 38.46 |
Previous Close | 38.88 |
Day's Range | 33.35 - 38.46 |
52-Week Range | 20.28 - 99.41 |
Beta | undefined |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also deve...
Analyst Forecast
According to 12 analyst ratings, the average rating for VKTX stock is "Buy." The 12-month stock price forecast is $109.5, which is an increase of 222.44% from the latest price.